Company
Headquarters: Oxford, United Kingdom
Employees: 92
| Company | Market Cap (USD) |
|---|---|
| Abbott | $216.15 B |
| Boston Scientific Corporation | $140.40 B |
| Stryker | $133.15 B |
| Medtronic | $123.20 B |
| Edwards Lifesciences Corporation | $50.10 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
NIOX Group Plc, engages in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNo), a biomarker for asthma worldwide. Its products include NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of FeNo level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022. NIOX Group Plc was incorporated in 2006 and is headquartered in Oxford, the United Kingdom.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | £36.8 M |
| EBITDA | £8.6 M |
| Gross Profit TTM | £26.5 M |
| Profit Margin | 29.08% |
| Operating Margin | 8.89% |
| Quarterly Revenue Growth | 13.90% |
NIOX Group Plc has the following listings and related stock indices.
Stock: LSE: NIOX